Wedbush analyst Andreas Argyrides reiterated a Buy rating on ARS Pharmaceuticals (SPRY – Research Report) today and set a price target of $15.00. The company’s shares closed last Friday at $6.83.
According to TipRanks, Argyrides is a 3-star analyst with an average return of 2.3% and a 33.59% success rate. Argyrides covers the Healthcare sector, focusing on stocks such as Ascendis Pharma, Aquestive Therapeutics, and MoonLake Immunotherapeutics.
ARS Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $14.00.
See today’s best-performing stocks on TipRanks >>
SPRY market cap is currently $652.7M and has a P/E ratio of -2.81.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Silverback Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on leveraging its ImmunoTAC technology platform to develop tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases.
Read More on SPRY:
